Other multiplicity-controlled endpoints
Skin Pain
SECONDARY

Percent change from baseline in WI-NRS at week 24 (PRIME and PRIME2)Proportion of patients with IGA PN-S 0 or 1 at week 12 (only multiplicity-controlled in PRIME2, secondary non-multiplicity-controlled endpoint in PRIME)Change from baseline in health-related QoL as measured by DLQI at week 24 (PRIME and PRIME2)Change from baseline in Skin Pain NRS at week 24 (PRIME and PRIME2)Change from baseline in HADS total score at week 24 (PRIME and PRIME2)Change from baseline in Sleep NRS at week 24 (only multiplicity-controlled in PRIME2, secondary non-multiplicity-controlled endpoint in PRIME)